Fluoxetine/Bupropion Suicide Attempters Major Depressive

氟西汀/安非他酮自杀未遂者重度抑郁症

• 批准号: 7024808
• 负责人: Michael F Grunebaum
• 金额: $ 17.67万
• 依托单位: COLUMBIA UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-02-06 至 2011-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7024808
• 关键词: aggression; amine oxidase (flavin); antidepressants; attention; behavioral /social science research tag; behavioral genetics; body physical activity; bupropion; clinical research; clinical trials; drug screening /evaluation; fluoxetine; genetic markers; genetic polymorphism; human subject; human therapy evaluation; impulsive behavior; job performance; major depression; mental disorder chemotherapy; neuropsychological tests; patient oriented research; pharmacogenetics; psychomotor function; serotonin transporter; suicide

DESCRIPTION (provided by applicant): Major depressive disorder (MOD) is a common and serious psychiatric illness. It is among the leading causes of disability and is the psychiatric disorder most frequently associated with suicide. Yet the treatment of MOD with antidepressant medication remains largely a trial-and-error process and little empirical evidence exists to guide treatment when suicide prevention is a priority. The purpose of this patient-oriented K-award is to develop and execute a program of research that will investigate clinical, neuropsychological and genetic predictors of response to different types of antidepressant medications in a high-risk sample of persons with MOD and a history of suicide attempt. Changes in clinical and neuropsychological components of depression and the diathesis for suicide will be compared during treatment with a serotonergic versus a non- serotonergic antidepressant. We will also determine whether functional polymorphisms in genes related to depression or the diathesis for suicide predict therapeutic effects of these antidepressants on mood or components of the diathesis for suicide. The principal investigator will carry out this program of research career development under the strong mentorship of Dr. J. John Mann (for training in the clinical neurobiology of depression and suicide). Active consultation and additional mentorship will come from Dr. A. John Rush (for training in antidepressant clinical trial design and execution), Dr. Bruce G. Pollock (for training in antidepressant pharmacogenetics), Dr. Joseph D. Terwilliger (for training in genetic epidemiology), Dr. John Keilp (for training in use of neuropsychological tests) and from Dr. Eva Petkova (for training in statistical analytic methods). This patient-oriented career development award will provide the principal investigator with the further experience and skills necessary to integrate clinical and scientific expertise in the field of depression and suicide clinical trials research. The long-term goal of this award is for the candidate to become an expert and independent clinical researcher on the treatment of depression with a special focus on suicide prevention.

描述（由申请人提供）：重度抑郁症（MOD）是一种常见且严重的精神病。它是残疾的主要原因之一，是最常见于自杀的精神疾病。然而，用抗抑郁药对MOD的治疗在很大程度上仍然是一种反复试验的过程，而在预防自杀是优先的情况下，几乎没有经验证据来指导治疗。这种面向患者的K-award的目的是制定和执行一项研究计划，该计划将研究具有MOD的高风险人群和自杀史的高风险样本中对不同类型抗抑郁药的反应的临床，神经心理学和遗传预测指标。抑郁症的临床和神经心理成分的变化以及在血清素能与非血清素能抗抑郁药治疗期间将比较自杀的素质。我们还将确定在与抑郁症有关的基因中的功能多态性或自杀的素质性是否预测这些抗抑郁药对自杀素质的情绪或成分的治疗作用。首席研究人员将在J. John Mann博士的强大指导下进行这项研究职业发展计划（用于抑郁和自杀的临床神经生物学培训）。主动咨询和其他指导将来自A. John Rush博士（接受抗抑郁药临床试验设计和执行培训），Bruce G. Pollock博士（用于抗抑郁药物遗传学的培训），Joseph D. Terwilliger博士（用于遗传流行病学的培训） 方法）。这项面向患者的职业发展奖将为首席研究人员提供进一步的经验和技能，以在抑郁症和自杀临床试验领域融合临床和科学专业知识所需的经验和技能。该奖项的长期目标是让候选人成为抑郁症治疗的专家和独立的临床研究人员，特别关注预防自杀。